Wednesday, July 26, 2017

Enter Title

Minimize
*|MC:SUBJECT|*
- PVRI Memorandum of Understanding
- ACEP online education program
- Clinical trial update: GRIPHON
View this email in your browser

Pulmonary Vascular Research Institute (PVRI) & PHSANZ announce formal memorandum of understanding.

The board of the PHSANZ is pleased to announce a new cooperative agreement with the Pulmonary Vascular Research Institute.

The aim of this memorandum of understanding is for the PVRI to support the work of the PHSANZ and to achieve the globalisation of their activities and collaboration with the rest of the world. Similarly, the PHSANZ will also participate in the global efforts of the PVRI as deemed necessary.


Members of the PHSANZ are encouraged to become a Fellow of
the PVRI so they may benefit from the various advantages of the fellowships, namely:
 
 Full access to the PVRI website with all its educational activities, news, and discussions.
 Allows members to register to all the PVRI meetings without registration fees.
 If requested, free subscription for 4 printed copies of the peer-reviewed PVRI Journal Pulmonary Circulation and 2 printed copies of the non-peer reviewed PVRI Journal PVRI Review annually
 To participate in their editorial board and other editorial activities on equal footing.
 A monthly newsletter
 Eligible to take advantage of all educational, travel or
research grants as regularly provided by PVRI

To request fellow membership & further information please visit the PVRI website or contact our CEO Geoff Strange.

PHSANZ announces collaboration with the Actelion Clinical Excellence Program 


The Pulmonary Hypertension Society of Australia/New Zealand (PHSANZ) encourages its members to utilize the web-based learning platform ACEP as a valuable educational resource for up skilling clinicians, particularly in areas outside their specialty interest, in the assessment and management of pulmonary hypertension in the Australasian setting.

Prof. Eli Gabbay is the Chair of ACEP which is now running “at arm’s length” from the sponsor for education on PHT.

Please click here for a link to the ACEP website and enrolment details.

The PHSANZ would like to thank Actelion for their effort in developing  this initiative.
 
For further information please contact the ACEP program coordinator Brad Dalton.

Clinical Trial Update: ACTELION PROVIDES UPDATE ON PHASE III GRIPHON STUDY WITH SELEXIPAG IN PULMONARY ARTERIAL HYPERTENSION - STUDY CONTINUES.


ALLSCHWIL, SWITZERLAND - 08 May 2013 - Actelion Ltd (SIX: ATLN) announced today that the Independent Data Monitoring Committee (DMC) has informed the company of its unanimous recommendation to continue the pivotal Phase III study, GRIPHON. In addition the DMC had no recommendations for any modification in study design or procedures. Full Press Release.
Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*

Our mailing address is:
*|HTML:LIST_ADDRESS_HTML|* *|END:IF|* unsubscribe from this list    update subscription preferences 

*|IF:REWARDS|* *|HTML:REWARDS|* *|END:IF|*
Copyright 2011 by PHSANZ